EUVIMEDEUVIMED entdecken
Crossref

Significance of Thyroid-Stimulating Immunoglobulin and Thyrotropin Receptor Antibody in Graves Disease

Rongguang Peng, Pu Xie iD, Zhou Jin, Wenzhong Zhou, Yanqiu Wang, Xinxin Chen, Qinglei Yin iD, Liyun Shen iD, Lingyang Meng, Lei Ye iD, Yulin Zhou iD, Shu Wang iD

The Journal of Clinical Endocrinology & Metabolism · 07.08.2025 · 110 (9) · e3002-e3010

DOI: 10.1210/clinem/dgae892 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 23.12.2024. Verfasst von Rongguang Peng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong Universit…. Hauptthemen laut MEDLINE: Graves Disease, Immunoglobulins, Thyroid-Stimulating, Receptors, Thyrotropin, Autoantibodies. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Thyroid-stimulating immunoglobulin (TSI) and thyrotropin receptor antibody (TRAb) are specific biomarkers for Graves disease (GD), but their clinical characteristics are not fully understood.

Objective

To clarify the clinical features and prognostic significance of TSI and TRAb in patients with GD.

Methods

We conducted a retrospective data analysis and a follow-up study. Medical records of patients newly diagnosed with GD were examined. TSI and TRAb correlations were assessed using Passing-Bablok regression and Bland-Altman plot. Patients were categorized into unresolved (Group A) and resolved (Group B) hyperthyroidism based on thyroid function after 1 month of therapy. The relationship between thyroid function and changes in TRAb and TSI was analyzed. Logistic regression identified relapse risk factors, including TSI levels at antithyroid drugs (ATDs) withdrawal in the follow-up study.

Results

Data from 957 patients (762 female and 195 male) revealed a strong correlation between TRAb and TSI (r = 0.873, P < .001). Compared to group B, group A showed minimal antibody decline (100% [interquartile range (IQR) 87.91%-115.1%] and 100% [IQR 85.03%-118.3%], respectively). Among 206 patients followed for over 12 months after ATD discontinuation, the relapse rate was 41.26%. Relapse was more frequent in patients with positive TSI (54.84% vs 35.42%, P < .05). Positive TSI levels at withdrawal, past history of GD, age, and mild thyroid-associated ophthalmopathy were independent relapse predictors.

Conclusion

TSI and TRAb are strongly correlated in GD, with slow antibody decline linked to unresolved hyperthyroidism. Discontinuing ATDs may be considered when both TSI and TRAb are negative.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graves DiseaseImmunoglobulins, Thyroid-StimulatingReceptors, ThyrotropinAutoantibodiesHumansFemaleMaleRetrospective StudiesAdultMiddle AgedFollow-Up StudiesPrognosisBiomarkersAntithyroid AgentsAgedRecurrenceYoung Adult

Stichwörter der Autor:innen

Graves diseaseprognosisthyroid-stimulating immunoglobulin (TSI)thyrotoxicosisthyrotropin receptor antibody (TRAb)

Substanzen

Immunoglobulins, Thyroid-StimulatingReceptors, ThyrotropinAutoantibodiesBiomarkersAntithyroid Agents

Autor:innen und Institutionen

  • Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
  • Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, Ruij…

ORCID-Profile: Pu Xie, Qinglei Yin, Liyun Shen, Lei Ye, Yulin Zhou, Shu Wang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Peng, R., Xie, P., Jin, Z., Zhou, W., Wang, Y., Chen, X., Yin, Q., Shen, L., Meng, L., Ye, L., Zhou, Y., & Wang, S. (2025). Significance of Thyroid-Stimulating Immunoglobulin and Thyrotropin Receptor Antibody in Graves Disease. The Journal of Clinical Endocrinology & Metabolism, 110(9), e3002-e3010. https://doi.org/10.1210/clinem/dgae892

Vancouver

Peng R, Xie P, Jin Z, Zhou W, Wang Y, Chen X, et al. Significance of Thyroid-Stimulating Immunoglobulin and Thyrotropin Receptor Antibody in Graves Disease. The Journal of Clinical Endocrinology & Metabolism. 2025;110(9):e3002-e3010. doi:10.1210/clinem/dgae892

BibTeX
@article{Peng2025,
  author = {Peng, Rongguang and Xie, Pu and Jin, Zhou and Zhou, Wenzhong and Wang, Yanqiu and Chen, Xinxin and Yin, Qinglei and Shen, Liyun and Meng, Lingyang and Ye, Lei and Zhou, Yulin and Wang, Shu},
  title = {Significance of Thyroid-Stimulating Immunoglobulin and Thyrotropin Receptor Antibody in Graves Disease},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  volume = {110},
  number = {9},
  pages = {e3002--e3010},
  doi = {10.1210/clinem/dgae892}
}
Kostenlos starten →